Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics
- PMID: 10320091
- DOI: 10.1080/00016489950181819
Arachidonic acid metabolism in nasal tissue and peripheral blood cells in aspirin intolerant asthmatics
Abstract
Aspirin intolerance (AI) is characterized by polypous rhinosinusitis, bronchial asthma and adverse reactions to aspirin. The common intolerance to all cyclo-oxygenase inhibitors allows us to focus study of the pathogenesis of AI on the metabolism of arachidonic acid (AA). We studied the metabolism of AA in nine aspirin intolerant asthmatics (AIA) and eight healthy volunteers (controls) by measuring prostaglandin E2 (PGE2) and peptido-leukotrienes (pLT = LTC4/D4/E4) in nasal tissue and peripheral blood cells (PBCs) using a specific immunoassay. In all patients with AI the tests were performed before and after bronchial provocation with lysine-ASA. In the control group the tests were done before and after 500 mg ASA p.o. The release of pLT in nasal polyps of AIA was found to be significantly higher than in normal mucosa of AIAs and controls. In every tissue a significant increase of pLT after aspirin challenge was observed. Nasal polyps of AIA show a significantly lower release of PGE2 than normal mucosa of AIAs and controls. Peripheral blood cells of AIA show a significantly higher release of pLT and a significantly lower release of PGE2 than PBCs of controls. Therefore clinical manifestations of AI may be based on an alteration of AA metabolism in AIA.
Similar articles
-
Aspirin intolerance and nasal polyposis.Curr Allergy Asthma Rep. 2002 Nov;2(6):488-93. doi: 10.1007/s11882-002-0089-8. Curr Allergy Asthma Rep. 2002. PMID: 12428645 Review.
-
Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge.Respir Med. 2010 Oct;104(10):1404-9. doi: 10.1016/j.rmed.2010.04.017. Epub 2010 May 10. Respir Med. 2010. PMID: 20452758
-
Dynamics of eicosanoids in peripheral blood cells during bronchial provocation in aspirin-intolerant asthmatics.Eur Respir J. 1999 Mar;13(3):638-46. doi: 10.1183/09031936.99.13363899. Eur Respir J. 1999. PMID: 10232440 Clinical Trial.
-
Eicosanoids from biopsy of normal and polypous nasal mucosa.Rhinology. 1996 Sep;34(3):166-70. Rhinology. 1996. PMID: 8938887
-
Mechanisms of aspirin sensitivity.Curr Allergy Asthma Rep. 2006 May;6(3):198-202. doi: 10.1007/s11882-006-0035-2. Curr Allergy Asthma Rep. 2006. PMID: 16579869 Review.
Cited by
-
Emerging Biomarkers Beyond Leukotrienes for the Management of Nonsteroidal Anti-inflammatory Drug (NSAID)-Exacerbated Respiratory Disease.Allergy Asthma Immunol Res. 2022 Mar;14(2):153-167. doi: 10.4168/aair.2022.14.2.153. Allergy Asthma Immunol Res. 2022. PMID: 35255534 Free PMC article. Review.
-
Aspirin Actions in Treatment of NSAID-Exacerbated Respiratory Disease.Front Immunol. 2021 Jun 25;12:695815. doi: 10.3389/fimmu.2021.695815. eCollection 2021. Front Immunol. 2021. PMID: 34305932 Free PMC article. Review.
-
Complementary Participation of Genetics and Epigenetics in Development of NSAID-exacerbated Respiratory Disease.Allergy Asthma Immunol Res. 2019 Nov;11(6):779-794. doi: 10.4168/aair.2019.11.6.779. Allergy Asthma Immunol Res. 2019. PMID: 31552714 Free PMC article. Review.
-
Lack of Efficacy of Symptoms and Medical History in Distinguishing the Degree of Eosinophilia in Nasal Polyps.J Allergy Clin Immunol Pract. 2017 Nov-Dec;5(6):1582-1588.e3. doi: 10.1016/j.jaip.2017.04.009. Epub 2017 May 10. J Allergy Clin Immunol Pract. 2017. PMID: 28499777 Free PMC article.
-
Release of cyclooxygenase-2 and lipoxin A4 from blood leukocytes in aspirin-exacerbated respiratory disease.Allergy Rhinol (Providence). 2016 Jan 1;7(3):158-163. doi: 10.2500/ar.2016.7.0172. Allergy Rhinol (Providence). 2016. PMID: 28107149 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
